Finanzen von Dermata Therapeutics Inc (DRMA)DRMADermata Therapeutics Inc

Evaluating the bottom line, Dermata Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -183.89%, provide a clear picture of how effectively DRMA converts its operational activities into shareholder value.

In the context of the broader market, DRMA competes directly with industry leaders such as BYAH and NXTS. With a market capitalization of $4.51M, it holds a significant position in the sector. When comparing efficiency, DRMA's gross margin of N/A stands against BYAH's 96.36% and NXTS's N/A. Such benchmarking helps identify whether Dermata Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Dermata's financial performance shows a troubling trend, with a net loss of $2.97 million in Q2 2026 and a consistent decline in net income over the past quarters. The company's current ratio is 2.81, indicating it can cover its short-term liabilities, but the overall financial health remains precarious.